首页> 美国卫生研究院文献>Cancer Science >Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase
【2h】

Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase

机译:抗体对淋巴细胞特异性蛋白酪氨酸激酶的细胞毒性T淋巴细胞表位肽的抗肿瘤活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Although humoral responses against CTL epitope peptides from lymphocyte‐specific protein tyrosine kinase (Lck) antigen have been observed in the majority of healthy donors and cancer patients, the biological activity of the antibody has not been determined. We investigated the biological activity of mAb against CTL epitope peptide of Lck antigen at positions 486‐494 (anti‐Lck‐486 mAb). This mAb induced dendritic cell maturation from murine bone marrow cells by the immune complex form in vitro, and inhibited tumor growth in association with a suppression of tumor‐infiltrating T cells, including T regulatory cells in a murine model using female BALB/cCrlCrlj mice (H‐2Kd). More potent tumor inhibition was observed when this mAb was given prior to peptide vaccination. These results may help to unveil the biological activity of anti‐Lck peptide antibodies against CTL epitope peptides.
机译:尽管在大多数健康供体和癌症患者中都观察到了来自淋巴细胞特异性蛋白酪氨酸激酶(Lck)抗原的针对CTL表位肽的体液反应,但尚未确定该抗体的生物学活性。我们研究了单克隆抗体对Lck抗原CTL表位肽在486-494位(抗Lck-486 mAb)的生物学活性。该mAb在体外通过免疫复合物的形式诱导鼠类骨髓细胞的树突状细胞成熟,并在雌性BALB / cCrlCrlj小鼠模型中抑制了肿瘤浸润性T细胞(包括T调节细胞)并抑制了肿瘤的生长( H‐2K d )。当在肽疫苗接种之前给予此mAb时,观察到更有效的肿瘤抑制作用。这些结果可能有助于揭示抗Lck肽抗体对CTL表位肽的生物学活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号